Yuichiro Kaneko
Overview
Explore the profile of Yuichiro Kaneko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
427
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tanaka Y, Takeuchi T, Izutsu H, Kaneko Y, Kato D, Fukuda M, et al.
Arthritis Res Ther
. 2021 Aug;
23(1):221.
PMID: 34429152
Background: Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with rheumatoid arthritis (RA). This study evaluated the effect of peficitinib...
12.
Toyoshima J, Kaibara A, Shibata M, Kaneko Y, Izutsu H, Nishimura T
Pharmacol Res Perspect
. 2021 Apr;
9(3):e00744.
PMID: 33929089
The aim was to analyze the relationship between peficitinib exposure and efficacy response according to American College of Rheumatology (ACR) 20 criteria and 28-joint disease activity score based on C-reactive...
13.
Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y, Chen Y, et al.
Rheumatol Ther
. 2021 Mar;
8(1):425-442.
PMID: 33656739
Introduction: This final analysis of a long-term extension (LTE) study assessed the safety, tolerability, and effectiveness of peficitinib (ASP015K), a pan-Janus kinase inhibitor, in Asian patients with rheumatoid arthritis (RA)....
14.
Takeuchi T, Tanaka Y, Erdman J, Kaneko Y, Saito M, Higashitani C, et al.
Arthritis Res Ther
. 2020 Oct;
22(1):252.
PMID: 33087159
Background: Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune condition characterized by joint synovial inflammation. Current treatments include methotrexate (MTX), biologic agents, and Janus kinase (JAK) inhibitors. However, these agents...
15.
Toyoshima J, Shibata M, Kaibara A, Kaneko Y, Izutsu H, Nishimura T
Br J Clin Pharmacol
. 2020 Oct;
87(4):2014-2022.
PMID: 33068028
Aims: To analyse the population pharmacokinetics (PK) of peficitinib in patients with rheumatoid arthritis (RA) and assess the potential PK covariates to identify the requirement for dose adjustment in RA...
16.
Takeuchi T, Tanaka Y, Rokuda M, Izutsu H, Kaneko Y, Fukuda M, et al.
Mod Rheumatol
. 2020 Oct;
31(3):543-555.
PMID: 33050760
Objective: To evaluate the safety of peficitinib for the treatment of rheumatoid arthritis (RA) in Asian patients. Methods: Safety data from one Phase 2b, two Phase 3, and one open-label...
17.
Shibata M, Toyoshima J, Kaneko Y, Oda K, Kiyota T, Kambayashi A, et al.
Clin Pharmacol Drug Dev
. 2020 Jul;
10(3):283-290.
PMID: 32618438
The marketed tablet formulation of peficitinib differs from the tablet used during the clinical trials. The bioequivalence of the marketed formulation and developmental tablet, and the food effect on the...
18.
Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y, Chen Y, et al.
Arthritis Res Ther
. 2020 Jun;
22(1):155.
PMID: 32576246
An amendment to this paper has been published and can be accessed via the original article.
19.
Shibata M, Toyoshima J, Kaneko Y, Oda K, Nishimura T
Eur J Clin Pharmacol
. 2020 May;
76(8):1135-1141.
PMID: 32472157
Purpose: Peficitinib is an oral pan-Janus kinase inhibitor for the treatment of rheumatoid arthritis. Co-administration of peficitinib with metformin, a type 2 diabetes therapy, can occur in clinical practice. Hepatic...
20.
Shibata M, Hatta T, Saito M, Toyoshima J, Kaneko Y, Oda K, et al.
Clin Drug Investig
. 2020 Apr;
40(5):469-484.
PMID: 32274653
Background And Objective: Peficitinib pharmacokinetics and pharmacodynamics have been characterized mainly in Caucasian subjects. This study investigated the pharmacokinetics, pharmacodynamics, safety, and tolerability of peficitinib in healthy Japanese subjects compared...